Prodromos I. Sidiropoulos

Irakleion, ESYE43, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 128 publications

Differential functional and lipidomic impact of tofacitinib and other disease-modifying antirheumatic drugs on HDL in rheumatoid arthritis.

Differential functional and lipidomic impact of tofacitinib and other disease-modifying antirheumatic drugs on HDL in rheumatoid arthritis.

Journal: Scientific reports

Published: April 06, 2026

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Journal: Annals of the rheumatic diseases

Published: January 30, 2026

Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.

Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.

Journal: Annals of the rheumatic diseases

Published: December 19, 2025

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.

Journal: Rheumatology and therapy

Published: November 18, 2025

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 20, 2025

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome.

Difficult to manage axial spondyloarthritis patients have high burden of pain-related comorbidities and adverse long-term outcome.

Journal: Arthritis research & therapy

Published: October 08, 2025

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study.

Distinct pattern of comorbidities hinders treatment target attainment in SLE through persistent disease activity and delayed glucocorticoid tapering: longitudinal data from a multicentre cohort study.

Journal: RMD open

Published: October 08, 2025

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.

Journal: Seminars in arthritis and rheumatism

Published: October 02, 2025

Molecular stratification and transcriptome-guided therapeutics in systemic lupus erythematosus with insufficient treatment response.

Molecular stratification and transcriptome-guided therapeutics in systemic lupus erythematosus with insufficient treatment response.

Journal: Journal of autoimmunity

Published: September 18, 2025

Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment.

Progression from at-risk state to clinical and severe systemic lupus erythematosus involves molecular dysregulations potentially reversible by biologics: implications for early diagnosis and treatment.

Journal: Annals of the rheumatic diseases

Published: July 11, 2025

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex.

Journal: Arthritis research & therapy

Published: June 27, 2025

Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage.

Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage.

Journal: RMD open

Published: June 10, 2025

Showing 1-12 of 128

Last Updated: 09/26/2026